Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Every row

Showing 3 of 382 rows. One row per study per exposure: a study that tested two different things appears twice, once for each.

Scroll the table sideways to see every column.

Research and outcomes, 3 rows. Every row links to its source.
Exposure Question Direction Outcome measured Design People Effect size, as the source reported it Source
Population burden (prevalence, incidence, lifetime risk) All modifiable factors together Prevention No direction reported
why

A pooled incidence and prevalence estimate with no exposure compared, so no direction is recorded.

Pooled incidence and prevalence of frontotemporal dementia meta-analysis not stated Pooled crude incidence for FTD was 2.28 (95% CI, 1.55-3.36) per 100 000 person-years and prevalence, 9.17 (95% CI, 3.59-23.42) per 100 000 people JAMA Neurology 2025
✓ Peer-reviewed PMID 40920400
Population burden (prevalence, incidence, lifetime risk) All modifiable factors together Prevention No direction reported
why

A pooled prevalence estimate with no exposure compared, so there is no direction to record.

Global prevalence of young-onset dementia (ages 30-64) meta-analysis 2,760,379 Age-standardized prevalence estimates increased from 1.1 per 100 000 population in the group aged 30 to 34 years to 77.4 per 100 000 population in the group aged 60 to 64 years. This gives an overall global age-standardized prevalence of 119.0 per 100 000 population in the age range of 30 to 64 years, corresponding to 3.9 million people aged 30 to 64 years living with YOD in the world JAMA Neurology 2021
✓ Peer-reviewed PMID 34279544
Polygenic risk / GWAS loci Genes (not modifiable) Prevention No direction reported
why

Locus-discovery genome-wide association study: it reports which genetic regions reached significance and no effect estimate for any exposure, so no direction is recorded. The study reports 14 new loci for clinically diagnosed AD and two from AD-by-proxy.

Genome-wide significant loci for clinically diagnosed AD and AD-by-proxy meta-analysis 432,374 not established — pubmed abstract lists the loci by name and reports no effect estimate. Alzheimer's & Dementia 2025
✓ Peer-reviewed PMID 39998322

How this table was built, and where it is weak →